StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) company profile

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

About Gain Therapeutics

Pharmaceutical Preparations, SIC 2834

Gain Therapeutics is a clinical-stage biotechnology company that utilizes its computational discovery platform, Magellan, to identify novel allosteric binding sites on disease-causing proteins. The company focuses on developing small molecule therapeutics, known as structurally targeted allosteric regulators, to treat conditions associated with protein misfolding and dysfunction. Its research and pipeline target central nervous system disorders, lysosomal storage disorders, metabolic diseases, and oncology indications. The company's lead drug candidate, GT-02287, is being developed for the treatment of Parkinson's disease with or without GBA1 mutations. Gain Therapeutics advances its programs and targets through collaborations with academic research institutions and industry licensing or co-development partners.

The company operates at a clinical stage, conducting Phase 1 clinical studies in healthy volunteers and patients with Parkinson's disease in Australia. In addition, its intellectual property portfolio includes granted patents across the United States, Europe, Japan, China, and Canada. The provided text does not disclose the location of the company's headquarters.

Summary of the business section of Gain Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Gain Therapeutics, Inc.
Headquarters
Bethesda, MD
Address
4800 Hampden Lane, Suite 200 20814
Phone
(301) 500-1556
Employees
20, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst& Young AG, Lugano, Switzerland

Stock & identifiers

Ticker
GANX
Exchange
Nasdaq
IPO date
Mar 22, 2021
Shares outstanding
44M, Jul 31, 2026
Public float
$53.20M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1819411
CUSIP
36269B105
ISIN
US36269B1052
FIGI
BBG00W7D7CJ9
Share class FIGI
BBG00W7D7CK7
EIN
85-1726310

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gene MackCEO, President, Director14,400
Jeanette WeidnerSee Remarks–
Gianluca FuggettaSee Remark–
Dov A. Goldstein MdDirector–
Hans Peter HaslerDirector–
Claude NicaiseDirector–
Jeffrey Scott RileyDirector30,000
Gwen A. MelincoffDirector–
Khalid IslamDirector930,784
Eric I. RichmanDirector304,458

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Gene Mack
Chief Executive Officer
$500.00K$802.82K$150.00K$14.32K$1.47M+99%
Gianluca Fuggetta
Principal Financial Officer
$241.35K$82.00K$21.72K–$345.07K-6%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 22, 2021
Securities offered
3,636,364
Exchange
Nasdaq
First trading day
Mar 19, 2021
First-day close
$12.20
Lock-up ends (est.)
Sep 15, 2021

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 20 full-time employees and one part-time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?